The tweet was deleted by the author.
But we saved everything 🙂.
Agenus reported its financial results for the third quarter of 2026, noting ongoing progress toward commencing Phase 3 clinical trials for the ROBBIN program.
The company also announced new clinical evidence from its NEST and UNICORN projects and the receipt of the first BOT plus BAL marketing authorizations in Armenia.
View post on X Loading...
In its recent Phase 2 trial for dMMR colon cancer, Agenus reported a 72 percent pathologic complete response and 83 percent major pathologic response rates, according to previous disclosures. The company had also announced plans to release its third quarter 2026 financial results on November 5, ahead of the U.S. market open, as detailed in a prior statement. These updates follow a series of clinical and regulatory developments for the firm.